12.09.16
Blis Technologies and Stratum Nutrition unveiled the results of a new clinical study in children reporting the beneficial effects of the probiotic, BLIS K12 (Streptococcus salivarius K12), on reducing the occurrences of streptococcal pharyngitis, along with other non-streptococcal infections. This study was recently published in Drug, Healthcare and Patient Safety, and supports an already extensive body of clinical research showing BLIS K12’s clinical benefits for reducing streptococcal pharyngitis and acute otitis media in children, as well as streptococcal pharyngitis in adults. The findings reported in this new study suggest that the use of BLIS K12 might be helpful in protecting against non-streptococcal infections, such as tracheitis, viral pharyngitis, rhinitis, acute respiratory infection (flu), laryngitis, and enteritis.
This pilot clinical trial was conducted by Di Pierro et al (Milan, Italy) on 124 male and female children between the ages of 3 and 10 years. Children who exhibited recurrent streptococcal pharyngitis during the previous year were given BLIS K12 probiotic (n=48), while the children who did not experience recurrent streptococcal pharyngitis during the previous year served as the untreated control group (n=76). The BLIS K12 probiotic was administered for 90 days with an additional 9-month follow-up.
The investigators reported that the actual episodes of streptococcal pharyngitis in children in the BLIS K12 probiotic group were reduced from 154 total episodes (average episode per child = 3.2) to 16 (average episode per child = 0.333). This clinically meaningful magnitude of effect corresponded to an approximate 90% reduction (P<0.01 vs control) in the occurrence of streptococcal pharyngitis at the end of the 3-month intervention and 9-month follow-up periods. In the untreated control group, actual episodes increased. In addition, children in the BLIS K12 probiotic group exhibited a significantly lower (P<0.01) number of episodes in tracheitis (95%), viral pharyngitis (90%), rhinitis (89%; P<0.05), flu (87%), laryngitis (98%), acute otitis media (100%) and enteritis (75%).
Dr. Joseph L. Evans (Founder & President, P & N Development Ventures, St. Louis, MO), commentws on the study, saying, “Although previous clinical trials have demonstrated that supplementation with BLIS K12 reliably reduces the episodes of streptococcal pharyngitis during a 3-month active supplementation period, these new findings demonstrate a persistent, protective effect even after cessation of usage. Since standard of care treatments for these unpleasant conditions are limited and are associated with absences from school and work, safe and effective prophylactic supplements would be welcomed by parents and practitioners.”
BLIS K12 is a unique strain of Streptococcus salivarius, a bacterial species commonly found in the oral cavity of healthy individuals. Supporting a beneficial microbiome in the oral cavity through BLIS K12 supplementation can be one of the best ways to maintain continued optimal oral hygiene and upper respiratory health.
This pilot clinical trial was conducted by Di Pierro et al (Milan, Italy) on 124 male and female children between the ages of 3 and 10 years. Children who exhibited recurrent streptococcal pharyngitis during the previous year were given BLIS K12 probiotic (n=48), while the children who did not experience recurrent streptococcal pharyngitis during the previous year served as the untreated control group (n=76). The BLIS K12 probiotic was administered for 90 days with an additional 9-month follow-up.
The investigators reported that the actual episodes of streptococcal pharyngitis in children in the BLIS K12 probiotic group were reduced from 154 total episodes (average episode per child = 3.2) to 16 (average episode per child = 0.333). This clinically meaningful magnitude of effect corresponded to an approximate 90% reduction (P<0.01 vs control) in the occurrence of streptococcal pharyngitis at the end of the 3-month intervention and 9-month follow-up periods. In the untreated control group, actual episodes increased. In addition, children in the BLIS K12 probiotic group exhibited a significantly lower (P<0.01) number of episodes in tracheitis (95%), viral pharyngitis (90%), rhinitis (89%; P<0.05), flu (87%), laryngitis (98%), acute otitis media (100%) and enteritis (75%).
Dr. Joseph L. Evans (Founder & President, P & N Development Ventures, St. Louis, MO), commentws on the study, saying, “Although previous clinical trials have demonstrated that supplementation with BLIS K12 reliably reduces the episodes of streptococcal pharyngitis during a 3-month active supplementation period, these new findings demonstrate a persistent, protective effect even after cessation of usage. Since standard of care treatments for these unpleasant conditions are limited and are associated with absences from school and work, safe and effective prophylactic supplements would be welcomed by parents and practitioners.”
BLIS K12 is a unique strain of Streptococcus salivarius, a bacterial species commonly found in the oral cavity of healthy individuals. Supporting a beneficial microbiome in the oral cavity through BLIS K12 supplementation can be one of the best ways to maintain continued optimal oral hygiene and upper respiratory health.
